Early clinical data on in vivo CAR-T cell therapy for multiple myeloma reveals key mechanistic insights and could mark the beginning of a new era of fast, streamlined and accessible immunotherapies.

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

A new study published online in the Journal of Intensive Medicine on June 17, 2025, highlights early and dynamic alterations in lymphocyte subsets following sepsis in elderly patients and their ...

The ability of immune cells—particularly CD8 + T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...

CD19 chimeric antigen receptor (CD19 CAR) T cell therapy has been shown to induce stable drug-free remission in patients with refractory autoimmune disease. The management of potential relapses is ...

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager ...

In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-target in vivo immune therapies shown to induce a rapid, long-lasting and potent expansion of specific ...

A dual-target CD19/BCMA chimeric antigen receptor T-cell therapy yielded “profound, sustained” remission in 11 patients with ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...